Lexicon Pharma (LXRX) Tops Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.02 -6.05%
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $376 million versus the consensus estimate of $360 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle reports earnings today: AI spending bet faces its toughest test yet
- Shoe Station Group Inc. (SHOE) Tops Q2 EPS by 11c ; Offers Guidance
- DA Davidson Reiterates Buy Rating on EVI Industries Inc. (EVI) Following Q4 Results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
